Document is current
Any future updates will be listed below
-
Authors
Novruzov, Emil https://orcid.org/0000-0003-1914-1332
Giesel, Frederik L.
Mamlins, Eduards
Watabe, Tadashi
Cardinale, Jens
Antke, Christina
Mori, Yuriko
Schupps, Nils
Pinto, Claudio
Soza-Ried, Cristian
Fernandez, Rene
Amaral, Horacio
Kramer, Vasko
Badinez, Leonardo
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 15 February 2026
First Online: 6 March 2026
Declarations
:
: All procedures performed in studies involving human participants were approved by the regional ethics committee board (Comité de Ética Científico; Servicio de Salud Metropolitano Oriente, Av. Salvador 364, Santiago, Chile). The ethics approval was issued on 19 June 2020 with the protocol number of CEC SSM Oriente/19062020. The study was carried out in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Oral and written informed consent for the enrollment to study were obtained from all patients on an individual-patient basis following national regulations.
: Oral and written informed consent for the publication of the study results were obtained from all patients on an individual-patient basis following national regulations.
: FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and holds shares of a consultancy group for iTheranostics. FLG is also an advisor at ABX, Telix, Alpha Fusion and SOFIE Biosciences. The other authors declare no conflict of interest regarding this manuscript.
